Schedule 13D ownership disclosure

AKARI THERAPEUTICS PLC

Security class unavailable · CUSIP: 00972G207

Event date: 2024-05-31

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
2,370,750,000
Percent of class
9.9900%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000908834-24-000173
Form type
SC 13D
Filer
Akari Therapeutics Plc
CIK
CIK 1541157
Filed
Jun 18, 2024
Reporting period
May 31, 2024
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub